| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Swapnali Chetia, Gaurab Bora. Δ 9-Tetrahydrocannabinol Toxicity and Validation of Cannabidiol on Brain Dopamine Levels: An Assessment on Cannabis Duplicity. Natural products and bioprospecting. vol 10. issue 5. 2020-10-16. PMID:32860199. |
Δ 9-tetrahydrocannabinol toxicity and validation of cannabidiol on brain dopamine levels: an assessment on cannabis duplicity. |
2020-10-16 |
2023-08-13 |
human |
| Kenneth Blum, Peter K Thanos, Marlene Oscar-Berman, Marcelo Febo, David Baron, Rajendra D Badgaiyan, Eliot Gardner, Zsolt Demetrovics, Claudia Fahlke, Brett C Haberstick, Kristina Dushaj, Mark S Gol. Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction. Journal of reward deficiency syndrome. vol 1. issue 3. 2020-10-01. PMID:27398406. |
david nutt and associates eloquently proposed that dopamine (da) may be central to psycho stimulant dependence and some what important for alcohol, but not important for opiates, nicotine or even cannabis. |
2020-10-01 |
2023-08-13 |
Not clear |
| Sanne J van der Steur, Albert Batalla, Matthijs G Bosson. Factors Moderating the Association Between Cannabis Use and Psychosis Risk: A Systematic Review. Brain sciences. vol 10. issue 2. 2020-09-28. PMID:32059350. |
moreover, several genotypes moderate the impact of cannabis use on psychosis risk, particularly those involved in the dopamine function, such as akt1. |
2020-09-28 |
2023-08-13 |
Not clear |
| Matthijs G Bossong, Hendrika H van Hell, Chris D Schubart, Wesley van Saane, Tabitha A Iseger, Gerry Jager, Matthias J P van Osch, J Martijn Jansma, René S Kahn, Marco P Boks, Nick F Ramse. Acute effects of ∆9-tetrahydrocannabinol (THC) on resting state brain function and their modulation by COMT genotype. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 29. issue 6. 2020-08-07. PMID:30975584. |
this finding suggests that prefrontal dopamine levels are involved in the susceptibility to acute effects of cannabis. |
2020-08-07 |
2023-08-13 |
human |
| Zhiqiang Liu, Yi Xu, Xiaofan Zhang, Jinfeng Miao, Jing Han, Zhou Zh. Riluzole blocks HU210-facilitated ventral tegmental long-term depression by enhancing glutamate uptake in astrocytes. Neuroscience letters. vol 704. 2020-02-05. PMID:30978452. |
previous studies in our research group suggested that astrocyte-mediated long-term depression (ltd) in ventral tegmental area (vta) dopamine neurons plays a pivotal role in the development of cannabis addiction. |
2020-02-05 |
2023-08-13 |
rat |
| Felicia Kamp, Lisa Proebstl, Nora Penzel, Kristina Adorjan, Andrej Ilankovic, Oliver Pogarell, Gabi Koller, Michael Soyka, Peter Falkai, Nikolaos Koutsouleris, Joseph Kambeit. Effects of sedative drug use on the dopamine system: a systematic review and meta-analysis of in vivo neuroimaging studies. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 44. issue 4. 2019-12-13. PMID:30188512. |
for cannabis users, there was no significant difference in receptor availability compared to controls and too few studies provided information on dopamine transporter availability or synthesis capacity. |
2019-12-13 |
2023-08-13 |
Not clear |
| Natasha L Mason, Eef L Theunissen, Nadia R P W Hutten, Desmond H Y Tse, Stefan W Toennes, Peter Stiers, Johannes G Ramaeker. Cannabis induced increase in striatal glutamate associated with loss of functional corticostriatal connectivity. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 29. issue 2. 2019-07-30. PMID:30553697. |
rodent studies suggest that Δ9-tetrahydrocannabinol (thc) activates dopaminergic neurons in the limbic system, subsequently enhancing dopamine, which is implicated in the rewarding effects of cannabis. |
2019-07-30 |
2023-08-13 |
Not clear |
| Marco Colizzi, Sagnik Bhattacharyy. Neurocognitive effects of cannabis: Lessons learned from human experimental studies. Progress in brain research. vol 242. 2019-03-29. PMID:30471680. |
also, direct and indirect evidence supports an alteration of different neurotransmitters, such as dopamine, glutamate, and gamma-aminobutyric acid, in modulating the manifestation of neurocognitive dysfunction and psychosis in the context of both acute and chronic cannabis exposure. |
2019-03-29 |
2023-08-13 |
human |
| Aviv Weinstein, Abigail Livny, Abraham Weizma. Brain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans: Evidence from Studies of Adult Users. Current pharmaceutical design. vol 22. issue 42. 2017-12-04. PMID:27549374. |
regular cannabis use resulted in reduced dopamine transporter occupancy and reduced dopamine synthesis but not in reduced striatal d2/d3 receptor occupancy compared with healthy control participants. |
2017-12-04 |
2023-08-13 |
human |
| Amine Benyamina, Laurent Karila, Geneviève Lafaye, Lisa Blech. Genetic Influences in Cannabis Use Disorder and Psychosis: Dopamine and Beyond. Current pharmaceutical design. vol 22. issue 42. 2017-12-04. PMID:27587204. |
genetic influences in cannabis use disorder and psychosis: dopamine and beyond. |
2017-12-04 |
2023-08-13 |
Not clear |
| Amine Benyamina, Laurent Karila, Geneviève Lafaye, Lisa Blech. Genetic Influences in Cannabis Use Disorder and Psychosis: Dopamine and Beyond. Current pharmaceutical design. vol 22. issue 42. 2017-12-04. PMID:27587204. |
one common denominator between cannabis use disorder and psychosis is dopamine dysfunction. |
2017-12-04 |
2023-08-13 |
Not clear |
| Amine Benyamina, Laurent Karila, Geneviève Lafaye, Lisa Blech. Genetic Influences in Cannabis Use Disorder and Psychosis: Dopamine and Beyond. Current pharmaceutical design. vol 22. issue 42. 2017-12-04. PMID:27587204. |
research has begun to link heightened dopamine reactivity with the psychotomimetic effects of cannabis. |
2017-12-04 |
2023-08-13 |
Not clear |
| P Seema. Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Translational psychiatry. vol 6. issue 10. 2017-12-04. PMID:27754480. |
cannabidiol is a partial agonist at dopamine d2high receptors, predicting its antipsychotic clinical dose. |
2017-12-04 |
2023-08-13 |
rat |
| P Seema. Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Translational psychiatry. vol 6. issue 10. 2017-12-04. PMID:27754480. |
although all current antipsychotics act by interfering with the action of dopamine at dopamine d2 receptors, two recent reports showed that 800 to 1000 mg of cannabidiol per day alleviated the signs and symptoms of schizophrenia, although cannabidiol is not known to act on dopamine receptors. |
2017-12-04 |
2023-08-13 |
rat |
| P Seema. Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Translational psychiatry. vol 6. issue 10. 2017-12-04. PMID:27754480. |
because these recent clinical findings may indicate an important exception to the general rule that all antipsychotics interfere with dopamine at dopamine d2 receptors, the present study examined whether cannabidiol acted directly on d2 receptors, using tritiated domperidone to label rat brain striatal d2 receptors. |
2017-12-04 |
2023-08-13 |
rat |
| P Seema. Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Translational psychiatry. vol 6. issue 10. 2017-12-04. PMID:27754480. |
it was found that cannabidiol inhibited the binding of radio-domperidone with dissociation constants of 11 nm at dopamine d2high receptors and 2800 nm at dopamine d2low receptors, in the same biphasic manner as a dopamine partial agonist antipsychotic drug such as aripiprazole. |
2017-12-04 |
2023-08-13 |
rat |
| P Seema. Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Translational psychiatry. vol 6. issue 10. 2017-12-04. PMID:27754480. |
it is concluded that the dopamine partial agonist action of cannabidiol may account for its clinical antipsychotic effects. |
2017-12-04 |
2023-08-13 |
rat |
| M A P Bloomfield, E Mouchlianitis, C J A Morgan, T P Freeman, H V Curran, J P Roiser, O D Howe. Salience attribution and its relationship to cannabis-induced psychotic symptoms. Psychological medicine. vol 46. issue 16. 2017-11-16. PMID:27628967. |
we therefore tested the hypothesis that cannabis users exhibit aberrant salience and explored the relationship between aberrant salience and dopamine synthesis capacity. |
2017-11-16 |
2023-08-13 |
Not clear |
| E van de Giessen, J J Weinstein, C M Cassidy, M Haney, Z Dong, R Ghazzaoui, N Ojeil, L S Kegeles, X Xu, N P Vadhan, N D Volkow, M Slifstein, A Abi-Dargha. Deficits in striatal dopamine release in cannabis dependence. Molecular psychiatry. vol 22. issue 1. 2017-09-29. PMID:27001613. |
deficits in striatal dopamine release in cannabis dependence. |
2017-09-29 |
2023-08-13 |
human |
| E van de Giessen, J J Weinstein, C M Cassidy, M Haney, Z Dong, R Ghazzaoui, N Ojeil, L S Kegeles, X Xu, N P Vadhan, N D Volkow, M Slifstein, A Abi-Dargha. Deficits in striatal dopamine release in cannabis dependence. Molecular psychiatry. vol 22. issue 1. 2017-09-29. PMID:27001613. |
to test whether cannabis dependence is associated with a similar dopaminergic deficit, we examined striatal and extrastriatal dopamine release in severely cannabis-dependent participants (cd), free of any comorbid conditions, including nicotine use. |
2017-09-29 |
2023-08-13 |
human |